The development of low titers of anti-cardiolipin antibodies during interferon alpha therapy in chronic hepatitis C has been reported (29), and APS may evolve during PEG IFN-α therapy (30). The gene discussed is IFNA1; the disease is autoimmune polyendocrinopathy.